Compare
Solesence, Inc. vs Axil Brands, Inc. vs cbdMD, Inc. vs Waldencast plc
| Latest fiscal year | Solesence, Inc. SLSN | Axil Brands, Inc. AXIL | cbdMD, Inc. YCBD | Waldencast plc MLKWF |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-05-31 | 2025-09-30 | 2025-12-31 |
| Revenue | $62.06M | $30.85M | $19.19M | $272.07M |
| Revenue growth (YoY) | +18.6% | +17.5% | -1.5% | -0.7% |
| Gross margin | 25.9% | 69.3% | 62.4% | 67.3% |
| Operating margin | 2.5% | 9.7% | -11.3% | -80.0% |
| Net margin | 2.9% | 8.8% | -10.6% | -84.4% |
| Net income | $1.79M | $2.70M | -$2.04M | -$229.75M |
| EPS (Diluted) | $0.02 | $0.33 | -$1.09 | -$2.01 |
| Operating cash flow | -$8.57M | -$9.6K | -$1.45M | -$12.82M |
| Free cash flow | n/a | -$89.0K | -$1.64M | -$16.25M |
| Cash & equivalents | $1.29M | $4.46M | $2.26M | $30.38M |
| Total assets | $50.05M | $17.96M | $10.42M | $746.16M |
| Total liabilities | n/a | $4.81M | $3.19M | $246.06M |
| Shareholders' equity | $17.63M | $13.14M | $7.23M | $461.88M |
| Return on year-end equity | 10.2% | 20.5% | -28.2% | -49.7% |
| Shares outstanding | 70.61M | 6.82M | 8.92M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Solesence, Inc. | Axil Brands, Inc. | cbdMD, Inc. | Waldencast plc |
|---|---|---|---|---|
| Latest | $62.06M Ended 2025-12-31 | $30.85M Ended 2026-05-31 | $19.19M Ended 2025-09-30 | $272.07M Ended 2025-12-31 |
| 1 year earlier | $52.35M Ended 2024-12-31 | $26.26M Ended 2025-05-31 | $19.48M Ended 2024-09-30 | $273.87M Ended 2024-12-31 |
| 2 years earlier | $37.30M Ended 2023-12-31 | $27.50M Ended 2024-05-31 | $24.16M Ended 2023-09-30 | $218.14M Ended 2023-12-31 |
| 3 years earlier | $37.32M Ended 2022-12-31 | $23.52M Ended 2023-05-31 | $35.40M Ended 2022-09-30 | n/a |
| 4 years earlier | $29.48M Ended 2021-12-31 | $2.34M Ended 2022-05-31 | $44.48M Ended 2021-09-30 | $142.47M Ended 2021-12-31 |